Article

Pilot study: Papillary thickness in optic nerve head edema

A spectral-domain optical coherence tomography (SD-OCT) star-pattern scan (SPS) acquisition protocol may be a more accurate and sensitive baseline measure for the diagnosis and follow-up of papilledema than presently used methods, according to the results of a pilot study, said Mazen Y. Choulakian, MD.

Fort Lauderdale, FL-A spectral-domain optical coherence tomography (SD-OCT) star-pattern scan (SPS) acquisition protocol may be a more accurate and sensitive baseline measure for the diagnosis and follow-up of papilledema than presently used methods, according to the results of a pilot study, said Mazen Y. Choulakian, MD.

Eight eyes from four newly diagnosed patients with papilledema secondary to idiopathic intracranial hypertension (IIH) were compared with 8 eyes from healthy controls using SD-OCT SPS and peripapillary total retinal thickness (PRT). PRT and PT were both evaluated with SD-OCT, and a macular cube acquisition protocol centered on the optic disc was used to evaluate PRT.

“Papillary thickness measured with SD-OCT SPS is significantly higher than PRT when compared [with] the control group,” said Dr. Choulakian, Ophthalmology, Centre Hospitalier Universitaire de Sherbrooke, QC, Canada. “We speculate that papillary thickness is a more sensitive sign to monitor disease progression and response to treatment than PRT since it represents more accurately the clinical evaluation of papilledema.”

The SPS protocol may allow for a more precise follow up of patients who are under treatment for IHH, may develop a recurrence, or have chronic papilledema and are at risk for hemorrhages.

“I think it could be a really innovative, interesting tool,” said Dr. Choulakian, adding that the SD-OCT SPS protocol would be practical in the clinic.

The findings from the small pilot study must be compared with other protocols. If the results are borne out, the new protocol may become widely adopted.

“I think OCT to papilledema will probably become what OCT is to macular edema today, a standard of care,” Dr. Choulakian concluded.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.